合成cefixime加载的PCL/HPMC混合纳米颗粒:一个受控释放研究和in vitro抗菌评估
Yashvi Naik1, Hem N Naik2, Jay Rai1
1Tarsadia Institute of Chemical Science, Uka Tarsadia University, Surat, India.
Journal of microencapsulation
|November 12, 2024
概括
这项研究开发了聚合物混合纳米颗粒,用于增强cefixime传递. 优化的配方显示了受控释放和有效的抗菌活性对大肠杆菌和黄金杆菌.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 生物技术是生物技术.
背景情况:
- 塞菲西姆是一种抗生素,在有效的药物输送方面面临着挑战.
- 改善药物度,剂量和时间对于改善治疗结果至关重要.
- 聚合物混合物为控制释放药物输送系统提供了潜在的潜力.
研究的目的:
- 为了研究聚合物混合物对cefixime体外释放特征的影响.
- 开发一种稳定有效的纳米颗粒系统,用于Cefixime的输送.
- 评估开发系统的物理化学特性和抗菌疗效.
主要方法:
- 使用修改的溶剂蒸发方法 (W/O/W双乳液) 制备了装有Cefixime的纳米粒子.
- 鉴定涉及FT-IR,泽塔潜力,TGA,TEM和XRD.
- 实验室释放研究和动力模型被用来分析释放机制.
主要成果:
- PH-4配方 (80:20 PCL/HPMC,0.5% PVA) 在30天内实现了81%的加载率和84.66%的受控释放.
- 这些纳米粒子表现出稳定的物理化学特性.
- 在体外抗菌试验显示,对大肠杆菌和黄金杆菌有显著的抑制区.
结论:
- 开发的PCL/HPMC纳米颗粒系统是有效和安全的,用于控制的cefixime输送.
- 该系统解决了抗生素药物输送方面的挑战,提高了治疗潜力.
- 这项研究强调了聚合物混合物在先进的药物输送应用中的前景.
相关概念视频
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...


